*In early-stage chronic kidney disease (CKD), albuminuria was found to be independently associated with increased risks of major adverse cardiovascular events (MACEs), heart failure (HF) and mortality*, found a recent study. 

While stage 2 CKD without albuminuria posed no notable risk, stage 2 CKD with albuminuria significantly elevated the risk of major adverse cardiovascular events (HR 1.32), heart failure (HR 1.79), and all-cause mortality (HR 1.51), paralleling the risks seen in stage 3A CKD without albuminuria.

These findings suggest that albuminuria should be considered over estimated glomerular filtration rate (eGFR) decline alone when assessing cardiovascular risk in early-stage CKD. 

By incorporating albuminuria into the diagnostic process, healthcare providers can better predict and manage cardiovascular risks, potentially improving patient outcomes and reducing cardiovascular complications.

Source: BMJ| [Read Full Story] (https://heart.bmj.com/content/early/2025/01/20/heartjnl-2024-324988?rss=1)